MADRID — Amgen’s Phase II trial of its bispecific T cell engager tarlatamab showed a response rate of 40% of patients with small cell lung cancer at the drug’s low dose, according to new research published Friday in the New England Journal of Medicine.
“One of the real challenges with small cell lung cancer is that even when it responds, the disease often very quickly relapses,” said David Reese, Amgen’s executive vice president for R&D. “And when it relapses, it can often be quite aggressive.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.